Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03831503 · ClinicalTrials.gov registry record · Phase 1
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03831503: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03831503 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03831503, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase 1, open label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers ages 18-60 years.
Interventions
- DEVICE CELLECTRA® 2000
- BIOLOGICAL INO-A002
- DEVICE Dengue Fever Antibodies (IgG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03831503
The ClinicalTrials.gov registry entry for NCT03831503 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CELLECTRA® 2000 is the first listed.
NCT03831503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03831503 about?
NCT03831503 is a clinical study titled "A Study of INO-A002 in Healthy Dengue Virus-naive Adults". Phase 1, open label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers ages 18-60 years.
What is the current status of trial NCT03831503?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-02-07. Estimated completion is 2022-10-03.
What interventions are being tested in trial NCT03831503?
The interventions under investigation include: CELLECTRA® 2000 (DEVICE), INO-A002 (BIOLOGICAL), Dengue Fever Antibodies (IgG) (DEVICE).
Who is sponsoring clinical trial NCT03831503?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.